[Proapoptotic antibodies as new therapeutic agents for tumor treatment]

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• The anti-CD95 antibody has shown success in preclinical mouse models for cancer treatment.
• Clinical translation requires the development of a human anti-CD95 antibody and rigorous safety assessments.

Purpose of the Study:

• To outline the necessary steps for developing and testing a human anti-CD95 antibody for clinical application.
• To investigate the safety and efficacy of anti-CD95 antibodies in combination with radiotherapy for various tumor types.

Main Methods:

• Production of a human anti-CD95 antibody.
• In vitro studies on normal human cells (including hepatocytes) to assess potential side effects at low doses.
• Clinical trials to evaluate dose escalation, hepatotoxicity, and therapeutic effects in combination with radiotherapy.

Main Results:

• The proposed approach leverages systemic anti-CD95 antibody administration amplified by local radiotherapy to induce cell death.
• Anti-CD95 antibodies primarily target tumor endothelia, initiating apoptosis.
• The strategy is applicable to prostate cancer, melanomas, and potentially many other tumor types.

Conclusions:

• A human anti-CD95 antibody is essential for clinical translation of this cancer therapy concept.
• Preclinical safety and efficacy studies are critical before human trials.
• The combination of anti-CD95 antibodies and radiotherapy offers a promising strategy for treating a wide range of cancers by targeting tumor vasculature.